Pardis Nematollahi, Mina Shakery, Amirhosein Kefayat, Parvin Goli
{"title":"CD49d表达与伊朗人群慢性淋巴细胞白血病患者临床病理特征的关系","authors":"Pardis Nematollahi, Mina Shakery, Amirhosein Kefayat, Parvin Goli","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Identification of factors affecting prognosis in chronic lymphocytic leukemia (CLL) is important for risk stratification of patients.</p><p><strong>Methods: </strong>In the present study, CD49d expression was analyzed by multi-color flow cytometry in 98 newly diagnosed and untreated CLL patients at the hematopathology ward. The patients were divided into two subgroups according to CD49d expression (30% cut off) and the association of this marker with the patients' clinicopathological properties were evaluated.</p><p><strong>Results: </strong>In this study, CD49d expression exhibited significant association with the Rai stage of the disease (P<0.0001), CD38 status (P<0.0001), hemoglobin level (P=0.0006), and platelet count (P=0.0016). The CD49d-positive patients presented in higher stages in comparison with CD49d-negative patients. Although only 1% of the CD49d-negative patients were CD38-positive, this proportion for CD49d-positive group was 69%. However, no significant correlation was observed between CD49d expression and patients' age (P=0.2031), gender (P=0.8119), and absolute lymphocytes count (P=0.1073).</p><p><strong>Conclusion: </strong>Therefore, CD49d is a grateful biomarker with high association with clinicopathological parameters in CLL patients.</p>","PeriodicalId":14352,"journal":{"name":"International journal of physiology, pathophysiology and pharmacology","volume":"12 1","pages":"32-39"},"PeriodicalIF":0.0000,"publicationDate":"2020-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076327/pdf/ijppp0012-0032.pdf","citationCount":"0","resultStr":"{\"title\":\"Association of CD49d expression with clinicopathological features of chronic lymphocytic leukemia patients in the Iranian population.\",\"authors\":\"Pardis Nematollahi, Mina Shakery, Amirhosein Kefayat, Parvin Goli\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Identification of factors affecting prognosis in chronic lymphocytic leukemia (CLL) is important for risk stratification of patients.</p><p><strong>Methods: </strong>In the present study, CD49d expression was analyzed by multi-color flow cytometry in 98 newly diagnosed and untreated CLL patients at the hematopathology ward. The patients were divided into two subgroups according to CD49d expression (30% cut off) and the association of this marker with the patients' clinicopathological properties were evaluated.</p><p><strong>Results: </strong>In this study, CD49d expression exhibited significant association with the Rai stage of the disease (P<0.0001), CD38 status (P<0.0001), hemoglobin level (P=0.0006), and platelet count (P=0.0016). The CD49d-positive patients presented in higher stages in comparison with CD49d-negative patients. Although only 1% of the CD49d-negative patients were CD38-positive, this proportion for CD49d-positive group was 69%. However, no significant correlation was observed between CD49d expression and patients' age (P=0.2031), gender (P=0.8119), and absolute lymphocytes count (P=0.1073).</p><p><strong>Conclusion: </strong>Therefore, CD49d is a grateful biomarker with high association with clinicopathological parameters in CLL patients.</p>\",\"PeriodicalId\":14352,\"journal\":{\"name\":\"International journal of physiology, pathophysiology and pharmacology\",\"volume\":\"12 1\",\"pages\":\"32-39\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-02-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076327/pdf/ijppp0012-0032.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International journal of physiology, pathophysiology and pharmacology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2020/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of physiology, pathophysiology and pharmacology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
Association of CD49d expression with clinicopathological features of chronic lymphocytic leukemia patients in the Iranian population.
Background: Identification of factors affecting prognosis in chronic lymphocytic leukemia (CLL) is important for risk stratification of patients.
Methods: In the present study, CD49d expression was analyzed by multi-color flow cytometry in 98 newly diagnosed and untreated CLL patients at the hematopathology ward. The patients were divided into two subgroups according to CD49d expression (30% cut off) and the association of this marker with the patients' clinicopathological properties were evaluated.
Results: In this study, CD49d expression exhibited significant association with the Rai stage of the disease (P<0.0001), CD38 status (P<0.0001), hemoglobin level (P=0.0006), and platelet count (P=0.0016). The CD49d-positive patients presented in higher stages in comparison with CD49d-negative patients. Although only 1% of the CD49d-negative patients were CD38-positive, this proportion for CD49d-positive group was 69%. However, no significant correlation was observed between CD49d expression and patients' age (P=0.2031), gender (P=0.8119), and absolute lymphocytes count (P=0.1073).
Conclusion: Therefore, CD49d is a grateful biomarker with high association with clinicopathological parameters in CLL patients.